Molecular detection of minimal residual disease is a strong predictive factor of relapse in childhood B-lineage acute lymphoblastic leukemia with medium risk features. A case control study of the International BFM study group
A. Biondi et al., Molecular detection of minimal residual disease is a strong predictive factor of relapse in childhood B-lineage acute lymphoblastic leukemia with medium risk features. A case control study of the International BFM study group, LEUKEMIA, 14(11), 2000, pp. 1939-1943
The medium-risk B cell precursor acute lymphoblastic leukemia (ALL) account
s for 50-60% of total childhood ALL and comprises the largest number of rel
apses still unpredictable with diagnostic criteria. To evaluate the prognos
tic impact of minimal residual disease (MRD) in this specific group, a case
control study was performed in patients classified and treated as medium (
or intermediate)-risk according to the criteria of national studies (ALL-BF
M 90, DCLSG protocol ALL-8, AIEOP-ALL 91), which includes a good day 7 trea
tment response. Standardized polymerase chain reaction (PCR) analysis of pa
tient-specific immunoglobulin and T cell receptor gene (TCR) rearrangements
were used as targets for semiquantitative estimation of MRD levels: greate
r than or equal to 10(-2), 10(-3), less than or equal to 10(-4) Twenty-nine
relapsing ALL patients were matched with the same number of controls by us
ing white blood cell count (WBC), age, sex, and time in first complete remi
ssion, as matching factors. MRD was evaluated at time-point 1 (end of proto
col Ia of induction treatment, ie 6 weeks from diagnosis) and time-point 2
(before consolidation treatment, ie 3 months from diagnosis). MRD-based hig
h risk patients (greater than or equal to 10(-3) at both time-points) were
more frequently present in the relapsed cases than in controls (14 vs 2), w
hile MRD-based low risk patients (MRD negative at both time-points) (1 vs 1
8) showed the opposite distribution. MRD-based high risk cases experienced
a significantly higher relapse rate than all other patients, according to t
he estimated seven-fold increase in the odds of failure, and a much higher
rate than MRD-based low risk patients (OR = 35.7; P = 0.003). Using the Cox
model, the prediction of the relapse-free interval at 4 years was 44.7%, 7
6.4% and 97.7% according to the different MRD categories. MRD-based risk gr
oup classification demonstrate their clinical relevance within the medium-r
isk B cell precursor ALL which account for the largest number of unpredicta
ble relapses, despite the current knowledge about clinical and biological c
haracteristics at diagnosis. Therefore, MRD detection during the first 3 mo
nths of follow-up can provide the tools to target more intensive therapy to
those patients at true risk of relapse.